Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) has been named a co-applicant in a competitive Terry Fox Research Institute grant awarded to advance Onco-Innovations’ SynoGraph(TM) oncology platform. The project, titled “Causal AI to Predict First-in-Human Clinical Outcomes from Preclinical and Real-World Clinico-Genomic Data,” will investigate whether causal AI can improve predictions of first-in-human clinical outcomes using preclinical and real-world clinico-genomic data. The collaboration includes the Michael Smith Genome Sciences Centre and the Centre de recherche du CHU de Québec-Université Laval as co-applicants, with Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) as lead applicant.
The grant supports a project with an estimated budget of $3.5 million and reimburses eligible costs up to 25% of that amount. Redwood AI will contribute proprietary data integration and physicochemical modelling methods to expand SynoGraph’s predictive capabilities. Academic partners will provide clinico-genomic and imaging data for research using federated learning, which is intended to support analysis while protecting data privacy. This approach allows multiple institutions to collaborate on sensitive patient data without compromising privacy, a critical consideration in oncology research.
The involvement of Redwood AI underscores the growing importance of artificial intelligence in drug development, particularly in oncology where predicting patient responses remains a major challenge. By leveraging causal AI, the project aims to bridge the gap between preclinical findings and human clinical trials, potentially accelerating the development of new cancer therapies. For Redwood AI, this collaboration represents a significant validation of its AI-powered platform for real-world applications across multiple critical industries. The company’s shares trade on the CSE under AIRX and on the OTCQB under RDWCF, and investors can follow the latest news and updates in the company’s newsroom at https://ibn.fm/RDWCF.
The Terry Fox Research Institute is a leading Canadian organization dedicated to cancer research, and its support lends credibility to the project. The use of federated learning is particularly noteworthy, as it addresses the dual goals of advancing research and maintaining data security. If successful, SynoGraph could become a valuable tool for pharmaceutical companies and researchers, potentially reducing the time and cost of bringing new cancer treatments to market.
Redwood AI’s participation highlights its expertise in data integration and chemical modelling, which are essential for building robust AI models. The project’s focus on causal AI—rather than merely correlative AI—could lead to more reliable predictions, as causal models aim to understand underlying mechanisms rather than just patterns. This is a key differentiator in the crowded field of AI in healthcare.
For more details, see the full announcement as covered by AINewsWire, a specialized communications platform focused on AI advancements. AINewsWire is part of IBN, which offers corporate communications solutions and social media distribution to millions of followers. The platform also provides press release enhancement and editorial syndication to 5,000+ outlets.
